The European Social Fund (ESF) three year project “Design of new pharmacomodulators and studies of their nanoassociates as transport forms” Nr 2009/0197/1DP/1.1.1.2.0/09/APIA/VIAA/014 started on December 1, 2009. The project unites multidisciplinary research teams of Latvian Institute of Organic Synthesis and Latvian Biomedical Research and Study Centre, including chemists, biologists, pharmacologists, physicists, mathematicians and computer specialists. The project aims to design new pharmacologically active molecules, develop new innovative methods of synthesis of different heterocyclic systems with a perspective to find new selective medicinal preparations for the treatment of oncological, cardiovascular and CNS diseases. The synthesis and investigations of properties of nanoparticles will be a contribution to one of the important scientific challenges of elaboration of effective self-assembling cationic amphiphilic compounds for drug and gene delivery. Total cost of the project – LVL 1,405,600. The research will be accomplished by November 30, 2012. The European Social Fund (ESF) three year project “Design of Inhibitors Zink Containing Enzymes and Investigation of Anti-Cancer Activity” No. 1DP/1.1.1.2.0/09/APIA/VIAA/023 started on December 1, 2009 The new multidisciplinary team has been established for the development of new patent-free anti-cancer agents based on innovative approach to use as pharmacological target zinc containing enzymes (ZCE). The aim of the project is to develop inhibitors of ZCE. This approach is widely recognised during last decade as a promising approach for the development of new anti-cancer agents for the treatment of tumours. In order to decrease the cost of development of new drugs as well as save natural resources the project also involves development of green chemistry and development of alternative methods for biological screening. For the efficient implementation of the project the team unites scientists from several scientific fields – mathematics and computer science, physics, chemistry, biology and pharmacology. Team leader Prof. Edvards Liepiņš Deputy team leader Dr. chem. Raivis Žalubovskis Total cost of the project – LVL 1,392,159. The research will be completed by November 30, 2012.
The European Social Fund (ESF) three year project “Design of new pharmacomodulators and studies of their nanoassociates as transport forms” Nr 2009/0197/1DP/1.1.1.2.0/09/APIA/VIAA/014 started on December 1, 2009.
The project unites multidisciplinary research teams of Latvian Institute of Organic Synthesis and Latvian Biomedical Research and Study Centre, including chemists, biologists, pharmacologists, physicists, mathematicians and computer specialists. The project aims to design new pharmacologically active molecules, develop new innovative methods of synthesis of different heterocyclic systems with a perspective to find new selective medicinal preparations for the treatment of oncological, cardiovascular and CNS diseases. The synthesis and investigations of properties of nanoparticles will be a contribution to one of the important scientific challenges of elaboration of effective self-assembling cationic amphiphilic compounds for drug and gene delivery. Total cost of the project – LVL 1,405,600. The research will be accomplished by November 30, 2012.
The European Social Fund (ESF) three year project “Design of Inhibitors Zink Containing Enzymes and Investigation of Anti-Cancer Activity” No. 1DP/1.1.1.2.0/09/APIA/VIAA/023 started on December 1, 2009 The new multidisciplinary team has been established for the development of new patent-free anti-cancer agents based on innovative approach to use as pharmacological target zinc containing enzymes (ZCE). The aim of the project is to develop inhibitors of ZCE. This approach is widely recognised during last decade as a promising approach for the development of new anti-cancer agents for the treatment of tumours. In order to decrease the cost of development of new drugs as well as save natural resources the project also involves development of green chemistry and development of alternative methods for biological screening. For the efficient implementation of the project the team unites scientists from several scientific fields – mathematics and computer science, physics, chemistry, biology and pharmacology.
Team leader Prof. Edvards Liepiņš
Deputy team leader Dr. chem. Raivis Žalubovskis
Total cost of the project – LVL 1,392,159. The research will be completed by November 30, 2012.